More recently, Wang’s group used a multidisciplinary approach to identify the “non-signaling open conformation” existing in KRAS–GTP hydrolysis as a potential target for the treatment of KRAS-dependent non-small-cell lung cancer and pancreatic cancer [14,15,16]. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.